4: Statement of changes in beneficial ownership of securities Post author:andrewkaretas Post published:August 17, 2023 Post category:SEC Filings Allogene Therapeutics, Inc. Continue Reading4: Statement of changes in beneficial ownership of securities
3: Initial filing by director officer or owner of more than ten percent. Post author:andrewkaretas Post published:August 17, 2023 Post category:SEC Filings Allogene Therapeutics, Inc. Continue Reading3: Initial filing by director officer or owner of more than ten percent.
4: Statement of changes in beneficial ownership of securities Post author:andrewkaretas Post published:August 15, 2023 Post category:SEC Filings Allogene Therapeutics, Inc. Continue Reading4: Statement of changes in beneficial ownership of securities
3: Initial filing by director officer or owner of more than ten percent. Post author:andrewkaretas Post published:August 14, 2023 Post category:SEC Filings Allogene Therapeutics, Inc. Continue Reading3: Initial filing by director officer or owner of more than ten percent.
4: Statement of changes in beneficial ownership of securities Post author:andrewkaretas Post published:August 9, 2023 Post category:SEC Filings Allogene Therapeutics, Inc. Continue Reading4: Statement of changes in beneficial ownership of securities
144: Filed by “insiders” prior intended sale of restricted stock. Non-EDGAR filing Post author:andrewkaretas Post published:August 7, 2023 Post category:SEC Filings Allogene Therapeutics, Inc. Continue Reading144: Filed by “insiders” prior intended sale of restricted stock. Non-EDGAR filing
10-Q: Quarterly report which provides a continuing view of a company's financial position Post author:andrewkaretas Post published:August 2, 2023 Post category:SEC Filings Allogene Therapeutics, Inc. Continue Reading10-Q: Quarterly report which provides a continuing view of a company's financial position
8-K: Report of unscheduled material events or corporate event Post author:andrewkaretas Post published:August 2, 2023 Post category:SEC Filings Allogene Therapeutics, Inc. Continue Reading8-K: Report of unscheduled material events or corporate event
SC 13G: A statement of beneficial ownership of common stock by certain persons Post author:andrewkaretas Post published:July 10, 2023 Post category:SEC Filings Allogene Therapeutics, Inc. Continue ReadingSC 13G: A statement of beneficial ownership of common stock by certain persons
144: Filed by “insiders” prior intended sale of restricted stock. Non-EDGAR filing Post author:andrewkaretas Post published:June 29, 2023 Post category:SEC Filings Allogene Therapeutics, Inc. Continue Reading144: Filed by “insiders” prior intended sale of restricted stock. Non-EDGAR filing
